T2 Biosystems to Report First Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Summary

T2 Biosystems (TTOO) will report its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will follow at 4:30 PM ET, allowing investors to access the live and archived webcast on their website. The company specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance genes, enhancing patient care through advanced technology. Their product line includes the T2Dx Instrument and various diagnostic panels powered by proprietary T2 Magnetic Resonance technology.

Positive

• T2 Biosystems is recognized as a leader in rapid sepsis detection, indicating strong market positioning.
• Products like the T2Dx Instrument and diagnostic panels suggest a diverse and innovative product pipeline.

Negative

• None.

LEXINGTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-545-0320 (U.S.) or 973-528-0002 (International) five to ten minutes prior to the start time, using the passcode: 927471.

About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx^® Instrument, T2Bacteria^® Panel, T2Candida^® Panel, T2Resistance^® Panel, and T2SARS-CoV-2™ Panel and are powered by the Company’s proprietary T2 Magnetic Resonance (T2MR^®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, T2Cauris™ Panel, T2Lyme™ Panel, and new products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406

 

FAQ

When will T2 Biosystems report its Q1 2022 financial results?

T2 Biosystems will report its Q1 2022 financial results on May 5, 2022, after market close.

What time is the T2 Biosystems conference call scheduled?

The conference call for T2 Biosystems is scheduled for 4:30 PM ET on May 5, 2022.

How can investors access the T2 Biosystems conference call?

Investors can access the conference call via a live and archived webcast on the T2 Biosystems website or by dialing the provided phone numbers.

What products does T2 Biosystems offer?

T2 Biosystems offers products like the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel, among others.

What technology powers T2 Biosystems' diagnostic products?

T2 Biosystems' diagnostic products are powered by their proprietary T2 Magnetic Resonance technology.